We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

185 hedge funds and large institutions have $1.02B invested in Arcus Biosciences in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 68 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $14.5M | Put options by funds: $7.25M

8% more capital invested

Capital invested by funds: $948M → $1.02B (+$74.9M)

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0.64% more ownership

Funds ownership: 70.89% → 71.53% (+0.64%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 68

1% less funds holding

Funds holding: 187 → 185 (-2)

Holders
185
Holders Change
-2
Holders Change %
-1.07%
% of All Funds
2.7%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
62
Reduced
68
Closed
25
Calls
$14.5M
Puts
$7.25M
Net Calls
+$7.26M
Net Calls Change
+$510K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$12.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M
3
BlackRock
BlackRock
New York
+$6.65M
4
SCM
Suvretta Capital Management
New York
+$5.76M
5
LGM
Logos Global Management
California
+$5.19M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$25.2M
2
American Century Companies
American Century Companies
Missouri
-$6.49M
3
N
Nuveen
North Carolina
-$5.28M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$4.44M
5
Barclays
Barclays
United Kingdom
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$192M +$6.65M +416,343 +4%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$90.3M -$819K -51,270 -1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$89.4M +$2.99M +186,898 +4%
State Street
4
State Street
Massachusetts
$81M +$632K +39,553 +0.9%
OCA
5
Octagon Capital Advisors
New York
$35.7M -$1.6M -100,000 -5%
Ameriprise
6
Ameriprise
Minnesota
$31.2M +$877K +54,881 +3%
IFA
7
Invus Financial Advisors
New York
$30.8M – – –
BC
8
Boxer Capital
California
$30.6M – – –
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$30.5M +$2.53M +158,094 +11%
Morgan Stanley
10
Morgan Stanley
New York
$26.8M +$12.7M +793,804 +130%
AllianceBernstein
11
AllianceBernstein
Tennessee
$22.7M +$4.02M +251,361 +27%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$21.8M +$1.03M +64,576 +6%
WP
13
Woodline Partners
California
$19.8M – – –
SCM
14
Suvretta Capital Management
New York
$18.3M +$5.76M +360,205 +60%
DC
15
Decheng Capital
California
$16.6M +$13.9M +869,790 New
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$14.7M +$12.2M +764,293 +17,148%
Goldman Sachs
17
Goldman Sachs
New York
$11.3M +$65.3K +4,083 +0.7%
BNP Paribas Asset Management
18
BNP Paribas Asset Management
France
$10.3M +$365K +22,863 +4%
Northern Trust
19
Northern Trust
Illinois
$10M +$115K +7,205 +1%
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$9.85M +$815K +51,003 +11%
Charles Schwab
21
Charles Schwab
California
$9.02M +$181K +11,341 +2%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$7.98M -$493K -30,828 -7%
UBS AM
23
UBS AM
Illinois
$7.61M -$118K -7,381 -2%
Macquarie Group
24
Macquarie Group
Australia
$7.24M – – –
Pictet Asset Management
25
Pictet Asset Management
Switzerland
$6.78M +$153K +9,549 +3%
1
2 3 4 5

RCUS Hedge Fund Activity: Q4 2023 in Review

185 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2023, worth a combined $1.02B — up 7.9% from $948M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RCUS positions and 25 closed out — a net gain of 1 holder — while 62 added to existing stakes and 68 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.2M sold.

  • 185 institutional investors held Arcus Biosciences (RCUS) as of Q4 2023, down from 187 in Q3 2023.
  • Funds reported $1.02B of Arcus Biosciences stock for Q4 2023, up 7.9% quarter-over-quarter.
  • 26 funds opened new Arcus Biosciences positions in Q4 2023 and 25 closed out, a net change of +1 holder.
  • The largest Arcus Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.7M added.
  • The largest Arcus Biosciences seller in Q4 2023 was PFM Health Sciences, an estimated $25.2M sold.

Based on aggregated 13F filings for Q4 2023.